Novartis' Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggest
Novartis’ BTK inhibitor Rhapsido has a chance of expanding from a chronic itch treatment to the multiple sclerosis market following wins in two identical Phase 3 trials. The pill significantly cut annualized relapse rates (ARR) ...
September 1, 2026 07:30 AM EDT R&DPharma Novartis' Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggest Elizabeth Cairns Senior biopharma journalist Novartis’ BTK inhibitor Rhapsido has a chance of expanding from a chronic itch treatment to the multiple sclerosis market following wins in two identical Phase … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that